Loading...

ADIL ADIAL PHARMACEUTICALS INC US FDA Inspections 8-K Filing

DL P

DL

ADIAL PHARMACEUTICALS INC

(ADIL)

2025 8-K

Show Summary

Show Summary

Voluntary Delisting

Financial Statements

Rights Offerings

Management Change

Financial Results

Business Development

Corporate Update

Share Sale Agreement

CEO Agreement Update

PK Study Completion

Equity Plan Update

Management Changes

Entry Into a Material Defin...

Departure of Directors

Warrant Inducement Agreement

Appointment of COO

Special Meeting of Stockhol...

Earnings Release

Annual Meeting and Amendmen...

Amendment to Form 8-K Filing

Securities Purchase Agreement

Recasting Financial Informa...

Acquisition Agreement

Investor Conferences

Earnings Reports

Completion of Acquisition o...

Reverse Stock Split

Presentation at Conference

Purchase Agreement with Alu...

Delisting Notice

Earnings Reports

Material Definitive Agreement

Special Meeting of Stockhol...

Financial Results Announcement

Agreement with The Keswick ...

Regulatory Strategy Update ...

Delisting Notice

Securities Purchase Agreement

Regulatory Meetings for AD04

Acquisition Agreement

External Links:

On February 25, 2025, Adial Pharmaceuticals announced that the FDA positively responded to its proposed in vitro bridging strategy for AD04, following a submission made on November 19, 2024, which is crucial for progressing to Phase 3 clinical trials

AI Assistant

ADIAL PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.